4.3 Article

Bronchodilator reversibility as a diagnostic test for adult asthma: findings from the population-based Tasmanian Longitudinal Health Study

期刊

ERJ OPEN RESEARCH
卷 7, 期 1, 页码 -

出版社

EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/23120541.00042-2020

关键词

-

资金

  1. National Health and Medical Research Council (NHMRC) of Australia
  2. University of Melbourne
  3. Clifford Craig Foundation
  4. Victorian Foundation
  5. Queensland Foundation
  6. Tasmanian Asthma Foundation
  7. Royal Hobart Hospital
  8. Helen MacPherson Smith Trust
  9. GlaxoSmithKline
  10. NHMRC Postgraduate Scholarship
  11. Royal Australian College of Physicians (RACP) Woolcock Scholarship

向作者/读者索取更多资源

Bronchodilator reversibility (BDR) was evaluated for its diagnostic accuracy in adult asthma and asthma-COPD overlap. The study found that a threshold of >= 12% and >= 200 mL from baseline provided the best balance between sensitivity and specificity for asthma (9% and 97%) and ACO (47% and 97%). A positive BDR test significantly altered the post-test probability of disease, especially in those with ACO.
Bronchodilator reversibility (BDR) is often used as a diagnostic test for adult asthma. However, there has been limited assessment of its diagnostic utility. We aimed to determine the discriminatory accuracy of common BDR cut-offs in the context of current asthma and asthma-COPD overlap (ACO) in a middle-aged community sample. The Tasmanian Longitudinal Health Study is a population-based cohort first studied in 1968 (n=8583). In 2012, participants completed respiratory questionnaires and spirometry (n=3609; mean age 53 years). Receiver operating characteristic (ROC) curves were fitted for current asthma and ACO using continuous BDR measurements. Diagnostic parameters were calculated for different categorical cut-offs. Area under the ROC curve (AUC) was highest when BDR was expressed as change in forced expiratory volume in 1 s (FEV1) as a percentage of initial FEV1, as compared with predicted FEV1. The corresponding AUC was 59% (95% CI 54-64%) for current asthma and 87% (95% CI 81-93%) for ACO. Of the categorical cut-offs examined, the European Respiratory Society/American Thoracic Society threshold (>= 12% from baseline and >= 200 mL) was assessed as providing the best balance between positive and negative likelihood ratios (LR+ and LR-, respectively), with corresponding sensitivities and specificities of 9% and 97%, respectively, for current asthma (LR + 3.26, LR- 0.93), and 47% and 97%, respectively, for ACO (LR+ 16.05, LR- 0.55). With a threshold of >= 12% and >= 200 mL from baseline, a positive BDR test provided a clinically meaningful change in the post-test probability of disease, whereas a negative test did not. BDR was more useful as a diagnostic test in those with co-existent post-bronchodilator airflow obstruction (ACO).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据